Zheng Quan Shi Bao Wang·2025-12-01 00:50Core Viewpoint - Lingke Pharmaceutical has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities and Jianyin International serving as joint sponsors [1] Group 1: Company Overview - Lingke Pharmaceutical is a China-based pharmaceutical company focused on developing novel drugs for oncology, immunology, and inflammatory diseases [1] - The company was founded by experienced drug development experts, indicating a strong background in drug discovery [1] Group 2: Product Development - Lingke Pharmaceutical has shown significant efficiency in advancing its product development pipeline [1] - The core products LNK01001 and LNK01004 have made substantial progress, with the first candidate expected to enter the preclinical stage [1] - The VAV1 program has entered the supportive research phase for new drug clinical trials [1]